Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of 1,4-Butanediol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,4-Butanediol SCHEMBL27437351 | 1.00 | TYMS (0.41) | TYMSSMN1; SMN2GPR84FFAR1FFAR4 | |
| Phosphoric Acid SCHEMBL9551052 | 0.96 | GPR84 (0.45) | TYMSSMN1; SMN2GPR84FFAR1FFAR4 | |
| 1,6-Hexanediol SCHEMBL27687126 | 0.96 | GPR84 (0.45) | TYMSSMN1; SMN2GPR84FFAR1FFAR4 | |
| Phosphoric Acid SCHEMBL19714406 | 0.96 | GPR84 (0.45) | TYMSSMN1; SMN2GPR84FFAR1FFAR4 | |
| 1,6-Hexanediol SCHEMBL20582374 | 0.96 | GPR84 (0.45) | TYMSSMN1; SMN2GPR84FFAR1FFAR4 | |
| Phosphoric Acid SCHEMBL28170316 | 0.96 | GPR84 (0.45) | TYMSSMN1; SMN2GPR84FFAR1FFAR4 | |
| Phosphoric Acid SCHEMBL16568053 | 0.92 | TYMS (0.41) | TYMSSMN1; SMN2GPR84FFAR1FFAR4 | |
| Phosphoric Acid SCHEMBL16567884 | 0.92 | TYMS (0.41) | TYMSSMN1; SMN2GPR84FFAR1FFAR4 | |
| Phosphoric Acid SCHEMBL8905153 | 0.92 | TYMS (0.41) | TYMSSMN1; SMN2GPR84FFAR1FFAR4 | |
| Phosphoric Acid SCHEMBL828102 | 0.92 | TYMS (0.41) | TYMSSMN1; SMN2GPR84FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2920 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043082-A2 | COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS | THE BROAD INSTITUTE, INC. (US) | 2025-02-27 | — | — | WO | claimed |
| EP-2895607-B1 | DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF | QUARK PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | claimed |
| EP-3434773-A2 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2019-01-30 | — | — | EP | claimed |
| US-10093923-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2018-10-09 | — | — | US | claimed |
| US-9611474-B2 | Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof | QUARK PHARMACEUTICALS, INC. (US) | 2017-04-04 | — | — | US | claimed |
| US-9328347-B2 | siRNA useful in the treatment of flavivirus infection | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2016-05-03 | — | — | US | claimed |
| EP-3012324-A2 | MODULATION OF HSP47 EXPRESSION | Nitto Denko Corporation (JP) | 2016-04-27 | — | — | EP | claimed |
| US-20160108399-A1 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2016-04-21 | — | — | US | claimed |
| US-9206424-B2 | Modulation of HSP47 expression | NITTO DENKO CORPORATION (JP) | 2015-12-08 | — | — | US | claimed |
| EP-2509991-B1 | MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORP (JP) | 2015-11-11 | — | — | EP | claimed |
| JP-2002526072-A | — | — | 2002-08-20 | — | — | JP | claimed |
| JP-2002520051-A | — | — | 2002-07-09 | — | — | JP | claimed |
| EP-1115859-A2 | HAIRPIN HYBRIDIZER MOLECULES FOR MODULATION OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-07-18 | — | — | EP | claimed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | claimed |
| EP-1098969-A2 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1071753-A2 | NUCLEIC ACID MOLECULES WITH NOVEL CHEMICAL COMPOSITIONS CAPABLE OF MODULATING GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-01-31 | — | — | EP | claimed |
| WO-2000017346-A2 | HAIRPIN HYBRIDIZER MOLECULES FOR MODULATION OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-03-30 | — | — | WO | claimed |
| WO-2000004141-A2 | USE OF NUCLEIC ACID MOLECULES AS ANTIVIRAL AGENTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | claimed |
| US-5998203-A | PARTICULARLY USEFUL FOR ENZYMATIC CLEAVAGE OF RNA OR SINGLE-STRANDED DNA. | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | claimed |
| WO-1999054459-A2 | NUCLEIC ACID MOLECULES WITH NOVEL CHEMICAL COMPOSITIONS CAPABLE OF MODULATING GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-10-28 | — | — | WO | claimed |